Key result
Adenosine added to thrombolysis cuts infarct size ~33% versus placebo, particularly in anterior infarctions.
Why the study?
Reperfusion therapy for acute myocardial infarction reduces mortality, but reperfusion itself may have deleterious effects.
Does adenosine as an adjunct to thrombolysis reduce infarct size in patients with acute myocardial infarction within 6 h of onset?
RCT (n=236)
Open-label
randomized
Does adenosine as an adjunct to thrombolysis reduce infarct size in patients with acute myocardial infarction within 6 h of onset?
Adenosine as an adjunct to thrombolysis significantly reduced infarct size in patients with acute myocardial infarction, particularly those with anterior infarction.
Answers are grounded in this paper and cite their sources.
Supports adjunctive adenosine with thrombolysis to limit infarct size in early AMI; extends reperfusion protection evidence from prior RCTs.
OBJECTIVES: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial was designed to test the hypothesis that adenosine as an adjunct to thrombolysis would reduce myocardial infarct size. BACKGROUND: Reperfusion therapy for acute myocardial infarction (MI) has been shown to reduce mortality, but reperfusion itself also may have deleterious effects. METHODS: The AMISTAD trial was a prospective, open-label trial of thrombolysis with randomization to adenosine or placebo in 236 patients within 6 h of infarction onset. The primary end point was infarct size as determined by Tc-99 m sestamibi single-photon emission computed tomography (SPECT) imaging 6+/-1 days after enrollment based on multivariable regression modeling to adjust for covariates. Secondary end points were myocardial salvage index and a composite of in-hospital clinical outcomes (death, reinfarction, shock, congestive heart failure or stroke). RESULTS: In all, 236 patients were enrolled. Final infarct size was assessed in 197 (83%) patients. There was a 33% relative reduction in infarct size (p = 0.03) with adenosine. There was a 67% relative reduction in infarct size in patients with anterior infarction (15% in the adenosine group vs. 45.5% in the placebo group) but no reduction in patients with infarcts located elsewhere (11.5% for both groups). Patients randomized to adenosine tended to reach the composite clinical end point more often than those assigned to placebo (22% vs. 16%; odds ratio, 1.43; 95% confidence interval, 0.71 to 2.89). CONCLUSIONS: Many agents thought to attenuate reperfusion injury have been unsuccessful in clinical investigation. In this study, adenosine resulted in a significant reduction in infarct size. These data support the need for a large clinical outcome trial.
No takes yet. Share an insight, caveat, or question.
Mahaffey et al. (1999) conducted an RCT in acute myocardial infarction (n=236). adenosine vs. placebo was evaluated on infarct size as determined by Tc-99 m sestamibi single-photon emission computed tomography (SPECT) imaging 6+/-1 days after enrollment (33% relative reduction, p=0.03). Adenosine as an adjunct to thrombolysis resulted in a 33% relative reduction in infarct size, with a 67% relative reduction observed in patients with anterior infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: